AMEX:VNRX

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

* Secured strongest-ever balance sheet with approximately $33.1 million in cash * Strengthened the Company's leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Initiated production of product components at scale at the Company's Silver One ...

2021-05-12 04:10 4985

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onWednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition to providing a bu...

2021-05-06 20:15 2694

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-31 20:30 1081

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-30 20:30 2043

VolitionRx Limited Appoints Two New Directors

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-30 04:10 2553

New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working ...

2021-03-17 20:00 4695

VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addition to providing ...

2021-03-16 20:30 4554

VolitionRx Limited to Present at Conferences in March 2021

AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at six conferences inMarch 2021. Duri...

2021-03-09 05:15 5212

VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers ...

2021-02-12 22:25 10954

VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

AUSTIN, Texas, Feb. 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers ...

2021-02-10 22:18 8800

VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts

AUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided a business update and announced the appointment of a new Chief Financial Officer, Mr. Terig Hughes, in addition to the appointment of Dr.Gaetan Michel as Chief Operating Officer, Mr. G...

2021-02-02 20:45 5821

VolitionRx Limited Opens its New Manufacturing Facility in Belgium

AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes,Belgium. Vol...

2021-01-25 21:45 7476

VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding

AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately$4 million from the Walloon Region and Namur Invest,Belgium. To date, Agencies from the Walloon Region have a...

2021-01-06 21:25 8784

VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors

AUSTIN, Texas, Dec. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the...

2020-12-03 21:30 9253

Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the l...

2020-12-01 21:45 8595

VolitionRx Limited to Present COVID-19 Data at MEDICA 2020

AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, has announced that Dr.Mark Eccleston, a founding sci...

2020-11-19 20:00 6757

Volition Veterinary Presents Expert Report Ahead of First Product Launch

* A Look to the Future of Cancer Diagnostics compiles insight from four veterinary cancer experts * Report provides insight into the clinical impact of early cancer detection, and recent advances * Experts also reviewed data on the Nu.Q™ Vet Cancer Screening Test, providing opinion and guid...

2020-11-10 21:00 5638

VolitionRx Limited Schedules Third Quarter 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, Nov. 9, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, November 13, at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter 2020, in addition to providing a b...

2020-11-09 21:00 4710

VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 21, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital ma...

2020-10-21 20:00 8937

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will host a capital...

2020-10-20 19:00 9816